Teva Pharmaceuticals to Cut 25% of Jobs in Huge Reshaping - The New York Times
Teva Recalls U.S.-Made Drugs Following Contamination Fears - Bloomberg
Teva looks to plug gap in its biomanufacturing network
Teva Recalls U.S.-Made Drugs Following Contamination Fears
Teva Recalls U.S.-Made Drugs Following Contamination Fears (3)
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva Pharmaceutical Industries is in talks to manufacture and distribute COVID vaccines | Fortune
Teva CEO says manufacturing cuts will keep coming even after $3B reduction achieved | FiercePharma
Teva plans the large-scale production of monoclonal antibodies in Ulm - Healthcare industry
Teva to cut 14,000 jobs | Business | Chemistry World
Taiyo Pharmaceutical Industry, Contract Manufacturing Plant - Pharmaceutical Technology
Teva, the world's largest generic drugmaker, is cutting 14,000 workers - Los Angeles Times
For pharma services firms, big assets can pose major risks
Teva Pharmaceuticals Sterile Manufacturing Facility, Ulm - Pharmaceutical Technology
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/7333YBOGCNAO7EPBSMO24XX7BA.jpg "Teva Pharmaceuticals to narrow focus on drugs, trim costs")
Teva Pharmaceuticals to narrow focus on drugs, trim costs
A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New York Times
Teva says it's in talks with COVID vaccine makers to help produce shots | The Times of Israel
Teva Pharmaceutical CEO says health-care is facing 'huge disruption'
Teva Eyes 25 Percent of the $750 Million EpiPen Market by Year's End | BioSpace
There May Be a Silver Lining to Teva's Woes | Ctech
Teva halts production at sterile injectables plant to address FDA concerns | FiercePharma
Drugmaker Teva makes $40B bid for rival Mylan
